Propionic Acid

Propionic Acid

SCHEMBL4155348

CCC(=O)O.O=c1[nH]c2ccc(S(=O)(=O)Nc3cccc(O)c3)cc2c2cc[nH]c12

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.44
BRAF P15056 1/20 0.44
GAA P10253 1/20 0.43
AR P10275 1/20 0.43
BRD4 O60885 6/20 0.43
TP53 P04637 4/20 0.42
MAPT P10636 4/20 0.42
PDE3A Q14432 1/20 0.42
KMT2A Q03164 1/20 0.42
UQCRB P14927 1/20 0.42
HSD17B2 P37059 1/20 0.42
LMNA P02545 2/20 0.42
THRB P10828 1/20 0.42
POLB P06746 1/20 0.41
SIRT2 Q8IXJ6 1/20 0.41
SIRT6 Q8N6T7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4720013 0.92 HSD17B2 (0.48) PKMBRAFGAAARBRD4
Propionic Acid SCHEMBL4163285 0.91 PKM (0.54) PKMBRAFGAAARBRD4
Propionic Acid SCHEMBL4162436 0.91 MAPT (0.52) PKMBRAFBRD4TP53MAPT
Propionic Acid SCHEMBL4162704 0.90 BRD4 (0.52) PKMBRAFBRD4TP53MAPT
Propionic Acid SCHEMBL4153953 0.90 PKM (0.55) PKMBRAFGAAARBRD4
Propionic Acid SCHEMBL4164331 0.88 MAPT (0.54) PKMGAABRD4TP53MAPT
Propionic Acid SCHEMBL4157631 0.86 BRAF (0.54) PKMBRAFGAAARTP53
Propionic Acid SCHEMBL4158106 0.85 BRD4 (0.60) BRD4PDE3A
Propionic Acid SCHEMBL4161017 0.85 BRAF (0.47) PKMBRAFGAAPDE3AKMT2A
Propionic Acid SCHEMBL4162506 0.85 BRD4 (0.50) PKMBRAFBRD4TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 PKM 276/4885BRAF 38/4885GAA 3035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.